High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

Denise M. Harnois, Paul Angulo, Roberta A. Jorgensen, Nicholas F. Larusso, Keith Lindor

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

OBJECTIVES: To assess the tolerability and efficacy of high-dose (25-30 mg/kg per day) ursodeoxycholic acid (UDCA) in patients with primary sclerosing cholangitis (PSC). METHODS: Thirty patients with PSC were enrolled in this pilot study and treated for 1 yr. Changes in the Mayo risk score at 1 yr of treatment and projected survival at 4 yr were compared with that observed in patients randomized to placebo (n = 52) or UDCA (n = 53) at a dose of 13-15 mg/kg per day. RESULTS: A marked improvement in serum alkaline phosphatase activity (1265 ± 172 vs 693 ± 110 U/L, p < 0.001), AST (161 ± 037 vs 77 ± 13 U/L, p = 0.001), albumin (4.0 ± 0.1 vs 4.2 ± 0.1 g/dl, p = 0.03), and total bilirubin (1.6 ± 0.3 vs 1.3 ± 0.2 mg/dl, p = 0.1) occurred at 1 yr of therapy with high-dose UDCA. Changes in the Mayo risk score after 1 yr of treatment were significantly different among the three groups (p < 0.001), and these changes would be translated into a significantly different expected survival at 4 yr (p = 0.05). This expected survival at 4 yr was significantly different between placebo and the dose of 25-30 mg/kg per day (p = 0.04), but not between placebo and the dose of 13-15 mg/kg per day (p = 0.4). High-dose UDCA was well tolerated. CONCLUSIONS: UDCA at a dose of 25-30 mg/kg per day may be of benefit for patients with PSC, and this regimen deserves further evaluation in a long-term, randomized, placebo-controlled trial.

Original languageEnglish (US)
Pages (from-to)1558-1562
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume96
Issue number5
DOIs
StatePublished - May 2001
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Sclerosing Cholangitis
Placebos
Survival
Therapeutics
Bilirubin
Alkaline Phosphatase
Albumins
Randomized Controlled Trials
Serum

ASJC Scopus subject areas

  • Gastroenterology

Cite this

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. / Harnois, Denise M.; Angulo, Paul; Jorgensen, Roberta A.; Larusso, Nicholas F.; Lindor, Keith.

In: American Journal of Gastroenterology, Vol. 96, No. 5, 05.2001, p. 1558-1562.

Research output: Contribution to journalArticle

Harnois, Denise M. ; Angulo, Paul ; Jorgensen, Roberta A. ; Larusso, Nicholas F. ; Lindor, Keith. / High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. In: American Journal of Gastroenterology. 2001 ; Vol. 96, No. 5. pp. 1558-1562.
@article{725c7b74d5644e6ea3ed5597bde95e89,
title = "High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis",
abstract = "OBJECTIVES: To assess the tolerability and efficacy of high-dose (25-30 mg/kg per day) ursodeoxycholic acid (UDCA) in patients with primary sclerosing cholangitis (PSC). METHODS: Thirty patients with PSC were enrolled in this pilot study and treated for 1 yr. Changes in the Mayo risk score at 1 yr of treatment and projected survival at 4 yr were compared with that observed in patients randomized to placebo (n = 52) or UDCA (n = 53) at a dose of 13-15 mg/kg per day. RESULTS: A marked improvement in serum alkaline phosphatase activity (1265 ± 172 vs 693 ± 110 U/L, p < 0.001), AST (161 ± 037 vs 77 ± 13 U/L, p = 0.001), albumin (4.0 ± 0.1 vs 4.2 ± 0.1 g/dl, p = 0.03), and total bilirubin (1.6 ± 0.3 vs 1.3 ± 0.2 mg/dl, p = 0.1) occurred at 1 yr of therapy with high-dose UDCA. Changes in the Mayo risk score after 1 yr of treatment were significantly different among the three groups (p < 0.001), and these changes would be translated into a significantly different expected survival at 4 yr (p = 0.05). This expected survival at 4 yr was significantly different between placebo and the dose of 25-30 mg/kg per day (p = 0.04), but not between placebo and the dose of 13-15 mg/kg per day (p = 0.4). High-dose UDCA was well tolerated. CONCLUSIONS: UDCA at a dose of 25-30 mg/kg per day may be of benefit for patients with PSC, and this regimen deserves further evaluation in a long-term, randomized, placebo-controlled trial.",
author = "Harnois, {Denise M.} and Paul Angulo and Jorgensen, {Roberta A.} and Larusso, {Nicholas F.} and Keith Lindor",
year = "2001",
month = "5",
doi = "10.1016/S0002-9270(01)02340-1",
language = "English (US)",
volume = "96",
pages = "1558--1562",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

AU - Harnois, Denise M.

AU - Angulo, Paul

AU - Jorgensen, Roberta A.

AU - Larusso, Nicholas F.

AU - Lindor, Keith

PY - 2001/5

Y1 - 2001/5

N2 - OBJECTIVES: To assess the tolerability and efficacy of high-dose (25-30 mg/kg per day) ursodeoxycholic acid (UDCA) in patients with primary sclerosing cholangitis (PSC). METHODS: Thirty patients with PSC were enrolled in this pilot study and treated for 1 yr. Changes in the Mayo risk score at 1 yr of treatment and projected survival at 4 yr were compared with that observed in patients randomized to placebo (n = 52) or UDCA (n = 53) at a dose of 13-15 mg/kg per day. RESULTS: A marked improvement in serum alkaline phosphatase activity (1265 ± 172 vs 693 ± 110 U/L, p < 0.001), AST (161 ± 037 vs 77 ± 13 U/L, p = 0.001), albumin (4.0 ± 0.1 vs 4.2 ± 0.1 g/dl, p = 0.03), and total bilirubin (1.6 ± 0.3 vs 1.3 ± 0.2 mg/dl, p = 0.1) occurred at 1 yr of therapy with high-dose UDCA. Changes in the Mayo risk score after 1 yr of treatment were significantly different among the three groups (p < 0.001), and these changes would be translated into a significantly different expected survival at 4 yr (p = 0.05). This expected survival at 4 yr was significantly different between placebo and the dose of 25-30 mg/kg per day (p = 0.04), but not between placebo and the dose of 13-15 mg/kg per day (p = 0.4). High-dose UDCA was well tolerated. CONCLUSIONS: UDCA at a dose of 25-30 mg/kg per day may be of benefit for patients with PSC, and this regimen deserves further evaluation in a long-term, randomized, placebo-controlled trial.

AB - OBJECTIVES: To assess the tolerability and efficacy of high-dose (25-30 mg/kg per day) ursodeoxycholic acid (UDCA) in patients with primary sclerosing cholangitis (PSC). METHODS: Thirty patients with PSC were enrolled in this pilot study and treated for 1 yr. Changes in the Mayo risk score at 1 yr of treatment and projected survival at 4 yr were compared with that observed in patients randomized to placebo (n = 52) or UDCA (n = 53) at a dose of 13-15 mg/kg per day. RESULTS: A marked improvement in serum alkaline phosphatase activity (1265 ± 172 vs 693 ± 110 U/L, p < 0.001), AST (161 ± 037 vs 77 ± 13 U/L, p = 0.001), albumin (4.0 ± 0.1 vs 4.2 ± 0.1 g/dl, p = 0.03), and total bilirubin (1.6 ± 0.3 vs 1.3 ± 0.2 mg/dl, p = 0.1) occurred at 1 yr of therapy with high-dose UDCA. Changes in the Mayo risk score after 1 yr of treatment were significantly different among the three groups (p < 0.001), and these changes would be translated into a significantly different expected survival at 4 yr (p = 0.05). This expected survival at 4 yr was significantly different between placebo and the dose of 25-30 mg/kg per day (p = 0.04), but not between placebo and the dose of 13-15 mg/kg per day (p = 0.4). High-dose UDCA was well tolerated. CONCLUSIONS: UDCA at a dose of 25-30 mg/kg per day may be of benefit for patients with PSC, and this regimen deserves further evaluation in a long-term, randomized, placebo-controlled trial.

UR - http://www.scopus.com/inward/record.url?scp=0034998596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034998596&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(01)02340-1

DO - 10.1016/S0002-9270(01)02340-1

M3 - Article

C2 - 11374699

AN - SCOPUS:0034998596

VL - 96

SP - 1558

EP - 1562

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -